Umibecestat
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
1
Sites
282
Countries
25
Endpoints
92
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 92 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 14 of 92 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
4
4
4
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| GS2A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease | Umibecestat Alzheimer’s disease | Amyloid biomarker required (PET/CSF) | Ph 2/3 | Terminated | 194 | Mar 2020 | - | results |
| GS1A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease | CAD106, Umibecestat Alzheimer’s disease | MMSE ≥24 | Ph 2/3 | Terminated | 129 | Apr 2020 | - | results |
| NCT02576639Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age | Umibecestat Alzheimer’s disease | Age 60-80 | Ph 2 | Completed | 11 | Mar 2016 | - | results |
Showing 1-3 of 3 trials